KRAS and cancer: Inthis work, we presented a cell-based platform for therapeuticdiscovery targeting KRAS mutants prevalent among many human cancers.2−5 We demonstrated that the KRAS(G12C) cell line is highly useful forthe development of assays for other KRAS mutants: we were able tosimply introduce the KRAS(G12D) mutation using CRISPR KI in the cellline described herein.